Amphion Innovations PLC Polarean update
24 August 2018 - 12:20AM
RNS Non-Regulatory
TIDMAMP
Amphion Innovations PLC
23 August 2018
Amphion Innovations plc
("Amphion" or "the Company")
Polarean Update
London and New York, 23 August 2018 - Amphion Innovations plc
(AIM: AMP), the developer of medical, life science, and technology
businesses, notes that its partner company Polarean Imaging plc
("Polarean") has announced that the first patient has been enrolled
in its Phase III FDA clinical trial which aims to demonstrate
non-inferiority of the Company's drug-device combination, using
hyperpolarised 129-Xenon (129Xe) gas MRI, against an approved
comparator.
This news means that Polarean is now in the process of its Phase
III clinical trial. Polarean is listed on the AIM market of the
London Stock Exchange under the ticker POLX.
Amphion currently holds c. 17 million shares, equivalent to
21.7% of the enlarged Share Capital of Polarean.
For further information please contact:
Amphion Innovations Tel: +1 (212) 210 6224
Charlie Morgan
Panmure Gordon Limited (Nominated Adviser Tel: +44 (0)20
and Corporate Broker) 7886 2500
Freddy Crossley / Ryan McCarthy / Emma
Earl (Corporate Finance)
Charlie Leigh-Pemberton (Corporate
Broking)
Northland Capital Partners Limited (Joint Tel: +44 (0)20 3861
Corporate Broker) 6625
David Hignell (Corporate Finance)
Vadim Alexandre (Corporate Broking)
Walbrook PR Tel: +44 (0)20 7933 8780 or
Anna Dunphy / Paul McManus amphion@walbrookpr.com
About Amphion Innovations plc - www.amphionplc.com
Amphion Innovations is a developer of medical, life science and
technology businesses. We use our extensive experience in company
building to invest and build shareholder value in high growth
companies in the US and UK. Amphion has significant shareholding in
a small number of Partner Companies developing proven technologies
targeting substantial commercial marketplaces. The Amphion model
has been refined to optimise the commercialisation of patents and
other intellectual property within the Partner Companies.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRALLFLSTTIVFIT
(END) Dow Jones Newswires
August 23, 2018 10:20 ET (14:20 GMT)
Amphion Innovations (LSE:AMP)
Historical Stock Chart
From Apr 2024 to May 2024
Amphion Innovations (LSE:AMP)
Historical Stock Chart
From May 2023 to May 2024
Real-Time news about Amphion Innovations Plc (London Stock Exchange): 0 recent articles
More Amphion News Articles